0 XP   0   0   0

Pharming Group NV










Financial Health of Pharming




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Richest
#299 / 1194

Total Sales
#121 / 1194

Making Money
#94 / 1194

Working Efficiently
#120 / 1194

Pharming Group NV
Buy, Hold or Sell?

Should you buy, hold or sell Pharming?

I guess you are interested in Pharming Group NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Pharming

Let's start. I'm going to help you getting a better view of Pharming Group NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Pharming Group NV even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Pharming Group NV is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Pharming Group NV. The closing price on 2022-11-28 was €1.218 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Pharming Group NV Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Pharming Group NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharming earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Net Profit Margin of 16.8% means that €0.17 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharming Group NV:

  • The MRQ is 16.8%. The company is making a huge profit. +2
  • The TTM is 14.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ16.8%TTM14.9%+1.9%
TTM14.9%YOY11.3%+3.6%
TTM14.9%5Y9.5%+5.4%
5Y9.5%10Y-5.7%+15.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.8%-223.6%+240.4%
TTM14.9%-281.7%+296.6%
YOY11.3%-344.8%+356.1%
5Y9.5%-450.1%+459.6%
10Y-5.7%-541.0%+535.3%
1.1.2. Return on Assets

Shows how efficient Pharming is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • 2.4% Return on Assets means that Pharming generated €0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharming Group NV:

  • The MRQ is 2.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.9%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.4%TTM1.9%+0.4%
TTM1.9%YOY1.4%+0.6%
TTM1.9%5Y1.3%+0.7%
5Y1.3%10Y-0.4%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4%-9.9%+12.3%
TTM1.9%-8.9%+10.8%
YOY1.4%-9.3%+10.7%
5Y1.3%-11.7%+13.0%
10Y-0.4%-12.7%+12.3%
1.1.3. Return on Equity

Shows how efficient Pharming is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • 4.5% Return on Equity means Pharming generated €0.05 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharming Group NV:

  • The MRQ is 4.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.5%TTM3.8%+0.7%
TTM3.8%YOY3.0%+0.8%
TTM3.8%5Y-4.2%+8.1%
5Y-4.2%10Y-25.5%+21.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5%-12.0%+16.5%
TTM3.8%-11.5%+15.3%
YOY3.0%-10.8%+13.8%
5Y-4.2%-14.2%+10.0%
10Y-25.5%-15.2%-10.3%

1.2. Operating Efficiency of Pharming Group NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharming is operating .

  • Measures how much profit Pharming makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • An Operating Margin of 37.7% means the company generated €0.38  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharming Group NV:

  • The MRQ is 37.7%. The company is operating very efficient. +2
  • The TTM is 18.7%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ37.7%TTM18.7%+19.1%
TTM18.7%YOY15.1%+3.5%
TTM18.7%5Y27.2%-8.5%
5Y27.2%10Y24.0%+3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ37.7%-207.3%+245.0%
TTM18.7%-271.0%+289.7%
YOY15.1%-325.9%+341.0%
5Y27.2%-454.0%+481.2%
10Y24.0%-537.1%+561.1%
1.2.2. Operating Ratio

Measures how efficient Pharming is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are €0.90 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharming Group NV:

  • The MRQ is 0.901. The company is less efficient in keeping operating costs low.
  • The TTM is 0.952. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.901TTM0.952-0.051
TTM0.952YOY0.949+0.002
TTM0.9525Y0.864+0.088
5Y0.86410Y0.898-0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9012.871-1.970
TTM0.9523.504-2.552
YOY0.9493.604-2.655
5Y0.8645.132-4.268
10Y0.8986.371-5.473

1.3. Liquidity of Pharming Group NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharming is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.40 means the company has €5.40 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharming Group NV:

  • The MRQ is 5.398. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.378. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.398TTM5.378+0.020
TTM5.378YOY4.353+1.025
TTM5.3785Y3.282+2.096
5Y3.28210Y2.959+0.323
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3985.117+0.281
TTM5.3785.755-0.377
YOY4.3535.854-1.501
5Y3.2826.511-3.229
10Y2.9596.222-3.263
1.3.2. Quick Ratio

Measures if Pharming is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Quick Ratio of 0.62 means the company can pay off €0.62 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharming Group NV:

  • The MRQ is 0.617. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.643. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.617TTM0.643-0.026
TTM0.643YOY0.587+0.056
TTM0.6435Y0.467+0.176
5Y0.46710Y0.448+0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6174.284-3.667
TTM0.6434.664-4.021
YOY0.5874.787-4.200
5Y0.4675.218-4.751
10Y0.4485.182-4.734

1.4. Solvency of Pharming Group NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharming assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharming to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.48 means that Pharming assets are financed with 47.6% credit (debt) and the remaining percentage (100% - 47.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharming Group NV:

  • The MRQ is 0.476. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.497. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.476TTM0.497-0.021
TTM0.497YOY0.536-0.038
TTM0.4975Y0.614-0.116
5Y0.61410Y0.656-0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4760.278+0.198
TTM0.4970.277+0.220
YOY0.5360.306+0.230
5Y0.6140.367+0.247
10Y0.6560.403+0.253
1.4.2. Debt to Equity Ratio

Measures if Pharming is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Debt to Equity ratio of 90.9% means that company has €0.91 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharming Group NV:

  • The MRQ is 0.909. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.991. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.909TTM0.991-0.082
TTM0.991YOY1.157-0.166
TTM0.9915Y2.020-1.028
5Y2.02010Y3.619-1.599
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9090.315+0.594
TTM0.9910.317+0.674
YOY1.1570.319+0.838
5Y2.0200.403+1.617
10Y3.6190.462+3.157

2. Market Valuation of Pharming Group NV

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Pharming generates.

  • Above 15 is considered overpriced but always compare Pharming to the Biotechnology industry mean.
  • A PE ratio of 79.48 means the investor is paying €79.48 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharming Group NV:

  • The EOD is 90.640. Neutral. Compare to industry.
  • The MRQ is 79.477. Neutral. Compare to industry.
  • The TTM is 114.318. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD90.640MRQ79.477+11.163
MRQ79.477TTM114.318-34.841
TTM114.318YOY-419.051+533.370
TTM114.3185Y0.223+114.095
5Y0.22310Y-4.927+5.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD90.640-8.986+99.626
MRQ79.477-9.792+89.269
TTM114.318-16.243+130.561
YOY-419.051-20.876-398.175
5Y0.223-16.665+16.888
10Y-4.927-14.732+9.805
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Pharming.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Pharming Group NV:

  • The MRQ is -108.918. Very Bad. -2
  • The TTM is 222.617. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ-108.918TTM222.617-331.535
TTM222.617YOY-15,144.427+15,367.043
TTM222.6175Y-2,981.851+3,204.468
5Y-2,981.85110Y-2,599.471-382.380
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-108.918-0.032-108.886
TTM222.6170.004+222.613
YOY-15,144.4270.016-15,144.443
5Y-2,981.8510.006-2,981.857
10Y-2,599.4710.003-2,599.474

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharming is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.61 means the investor is paying €3.61 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharming Group NV:

  • The EOD is 4.119. Neutral. Compare to industry.
  • The MRQ is 3.612. Neutral. Compare to industry.
  • The TTM is 3.008. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD4.119MRQ3.612+0.507
MRQ3.612TTM3.008+0.604
TTM3.008YOY4.369-1.361
TTM3.0085Y9.295-6.287
5Y9.29510Y12.650-3.355
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.1191.835+2.284
MRQ3.6122.006+1.606
TTM3.0082.774+0.234
YOY4.3693.453+0.916
5Y9.2952.713+6.582
10Y12.6502.402+10.248
2. Total Gains per Share

2.4. Latest News of Pharming Group NV

Does Pharming Group NV still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Pharming Group NV to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-28
08:36
Investing in Pharming Group (AMS:PHARM) a year ago would have delivered you a 59% gainRead
2022-11-23
14:50
Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's WhyRead
2022-11-08
18:20
Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?Read
2022-10-31
05:55
Pharming Group N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsRead

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharming Group NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0010.012-93%0.009-91%0.014-94%0.012-93%
Book Value Growth---0.0350.007-612%0.003-1183%0.105-134%-0.064+81%
Book Value Per Share--0.2960.282+5%0.239+24%0.175+69%0.150+97%
Book Value Per Share Growth--0.0030.043-93%0.040-93%0.138-98%-0.025+943%
Current Ratio--5.3985.378+0%4.353+24%3.282+64%2.959+82%
Debt To Asset Ratio--0.4760.497-4%0.536-11%0.614-22%0.656-27%
Debt To Equity Ratio--0.9090.991-8%1.157-21%2.020-55%3.619-75%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0130.011+17%0.007+88%0.007+89%0.003+339%
Eps Growth---0.7300.337-317%-4.844+564%-0.267-63%-0.156-79%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.1680.149+12%0.113+48%0.095+76%-0.057+134%
Operating Margin--0.3770.187+102%0.151+149%0.272+39%0.240+58%
Operating Ratio--0.9010.952-5%0.949-5%0.864+4%0.898+0%
Pb Ratio4.119+12%3.6123.008+20%4.369-17%9.295-61%12.650-71%
Pe Ratio90.640+12%79.477114.318-30%-419.051+627%0.223+35503%-4.927+106%
Peg Ratio---108.918222.617-149%-15144.427+13804%-2981.851+2638%-2599.471+2287%
Price Per Share1.218+12%1.0680.848+26%1.037+3%1.022+5%0.916+17%
Price To Total Gains Ratio1412.723+12%1238.742376.954+229%499.853+148%216.235+473%150.648+722%
Profit Growth---79.57739.237-303%-504.789+534%-28.956-64%-16.813-79%
Quick Ratio--0.6170.643-4%0.587+5%0.467+32%0.448+38%
Return On Assets--0.0240.019+22%0.014+72%0.013+87%-0.004+116%
Return On Equity--0.0450.038+19%0.030+49%-0.042+193%-0.255+662%
Revenue Growth--0.0400.011+271%-0.083+306%-0.014+136%0.025+61%
Total Gains Per Share--0.0010.012-93%0.009-91%0.014-94%0.012-93%
Total Gains Per Share Growth---8.674-2.533-71%-6.066-30%-1.748-80%-0.630-93%
Usd Book Value--200273636.907191057733.284+5%161796113.029+24%118439627.673+69%101701082.669+97%
Usd Book Value Change Per Share--0.0010.013-93%0.010-91%0.015-94%0.013-93%
Usd Book Value Per Share--0.3070.293+5%0.248+24%0.181+69%0.156+97%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0140.012+17%0.007+88%0.007+89%0.003+339%
Usd Price Per Share1.265+12%1.1090.881+26%1.077+3%1.061+5%0.951+17%
Usd Profit--9101892.4447541989.495+21%4837827.486+88%4787827.156+90%2049936.005+344%
Usd Revenue--54243318.57849192073.302+10%43718348.212+24%43071042.083+26%38656785.827+40%
Usd Total Gains Per Share--0.0010.013-93%0.010-91%0.015-94%0.013-93%
 EOD+2 -3MRQTTM+20 -12YOY+22 -105Y+19 -1310Y+21 -11

3.2. Fundamental Score

Let's check the fundamental score of Pharming Group NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1590.640
Price to Book Ratio (EOD)Between0-14.119
Net Profit Margin (MRQ)Greater than00.168
Operating Margin (MRQ)Greater than00.377
Quick Ratio (MRQ)Greater than10.617
Current Ratio (MRQ)Greater than15.398
Debt to Asset Ratio (MRQ)Less than10.476
Debt to Equity Ratio (MRQ)Less than10.909
Return on Equity (MRQ)Greater than0.150.045
Return on Assets (MRQ)Greater than0.050.024
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.951
Ma 20Greater thanMa 501.136
Ma 50Greater thanMa 1001.071
Ma 100Greater thanMa 2001.044
OpenGreater thanClose1.165
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets382,323
Total Liabilities182,069
Total Stockholder Equity200,254
 As reported
Total Liabilities 182,069
Total Stockholder Equity+ 200,254
Total Assets = 382,323

Assets

Total Assets382,323
Total Current Assets252,048
Long-term Assets252,048
Total Current Assets
Cash And Cash Equivalents 188,703
Net Receivables 28,828
Inventory 33,506
Other Current Assets 1,011
Total Current Assets  (as reported)252,048
Total Current Assets  (calculated)252,048
+/-0
Long-term Assets
Property Plant Equipment 27,782
Long Term Investments 10,776
Other Assets 21,594
Long-term Assets  (as reported)130,275
Long-term Assets  (calculated)60,152
+/- 70,123

Liabilities & Shareholders' Equity

Total Current Liabilities46,694
Long-term Liabilities135,375
Total Stockholder Equity200,254
Total Current Liabilities
Short Long Term Debt 1,627
Accounts payable 42,744
Total Current Liabilities  (as reported)46,694
Total Current Liabilities  (calculated)44,371
+/- 2,323
Long-term Liabilities
Long term Debt 120,005
Capital Lease Obligations Min Short Term Debt17,550
Other Liabilities 143
Long-term Liabilities Other 143
Long-term Liabilities  (as reported)135,375
Long-term Liabilities  (calculated)137,841
+/- 2,466
Total Stockholder Equity
Common Stock7,482
Total Stockholder Equity (as reported)200,254
Total Stockholder Equity (calculated)7,482
+/- 192,772
Other
Capital Stock7,482
Common Stock Shares Outstanding 652,414
Net Invested Capital 321,886
Net Tangible Assets 130,131
Net Working Capital 205,354



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
126,783
131,438
126,966
139,956
166,190
170,681
181,367
192,717
214,569
199,560
205,795
220,814
228,210
303,934
317,112
319,348
340,758
348,519
346,231
345,637
350,552
392,798
393,898
382,323
382,323393,898392,798350,552345,637346,231348,519340,758319,348317,112303,934228,210220,814205,795199,560214,569192,717181,367170,681166,190139,956126,966131,438126,783
   > Total Current Assets 
62,190
66,105
61,115
73,658
88,251
94,437
105,476
115,546
115,440
101,689
101,215
101,788
106,503
178,909
195,391
197,623
214,343
223,343
211,137
208,804
249,444
250,948
256,980
252,048
252,048256,980250,948249,444208,804211,137223,343214,343197,623195,391178,909106,503101,788101,215101,689115,440115,546105,47694,43788,25173,65861,11566,10562,190
       Cash And Cash Equivalents 
31,889
27,358
24,997
38,389
58,657
58,456
65,539
71,025
80,311
65,264
63,886
62,967
66,299
133,834
152,782
154,795
167,068
175,941
158,304
158,037
169,335
189,674
189,964
188,703
188,703189,964189,674169,335158,037158,304175,941167,068154,795152,782133,83466,29962,96763,88665,26480,31171,02565,53958,45658,65738,38924,99727,35831,889
       Net Receivables 
11,386
19,846
18,645
17,274
10,183
14,370
16,775
23,570
16,001
22,783
24,624
26,985
23,458
30,564
26,386
26,446
25,965
28,050
31,569
28,285
27,591
31,445
32,878
28,828
28,82832,87831,44527,59128,28531,56928,05025,96526,44626,38630,56423,45826,98524,62422,78316,00123,57016,77514,37010,18317,27418,64519,84611,386
       Inventory 
17,941
18,901
17,473
17,995
18,334
21,611
23,162
20,951
17,315
13,642
12,705
11,836
14,467
14,511
16,223
16,382
17,229
18,533
20,434
21,636
27,310
29,607
33,929
33,506
33,50633,92929,60727,31021,63620,43418,53317,22916,38216,22314,51114,46711,83612,70513,64217,31520,95123,16221,61118,33417,99517,47318,90117,941
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
97,871
104,580
119,026
121,707
125,025
121,721
121,725
126,415
125,176
135,094
136,833
130,467
141,850
136,918
130,275
130,275136,918141,850130,467136,833135,094125,176126,415121,725121,721125,025121,707119,026104,58097,871000000000
       Property Plant Equipment 
6,043
6,442
7,104
7,815
8,234
7,970
8,291
8,298
8,402
12,167
15,022
14,762
14,532
14,270
14,032
16,512
17,632
18,665
31,635
32,669
33,165
31,897
29,958
27,782
27,78229,95831,89733,16532,66931,63518,66517,63216,51214,03214,27014,53214,76215,02212,1678,4028,2988,2917,9708,2347,8157,1046,4426,043
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
5,377
5,517
5,307
5,515
5,616
5,682
5,796
5,722
6,104
8,630
8,787
7,403
11,631
10,776
10,77611,6317,4038,7878,6306,1045,7225,7965,6825,6165,5155,3075,5175,3770000000000
       Intangible Assets 
55,889
56,148
55,855
56,735
53,043
56,272
55,843
56,322
50,198
52,062
51,516
67,806
70,809
0
0
0
76,615
0
0
0
74,044
0
0
0
00074,04400076,61500070,80967,80651,51652,06250,19856,32255,84356,27253,04356,73555,85556,14855,889
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
97,871
104,580
119,026
121,707
125,025
2,272
1,256
415
735
415
121
-439
797
746
197
197746797-4391214157354151,2562,272125,025121,707119,026104,58097,871000000000
> Total Liabilities 
99,316
102,498
120,202
133,744
147,388
139,074
140,702
144,544
152,818
130,493
128,305
130,339
123,531
188,314
189,543
183,095
191,381
189,833
179,715
178,786
180,341
198,777
194,228
182,069
182,069194,228198,777180,341178,786179,715189,833191,381183,095189,543188,314123,531130,339128,305130,493152,818144,544140,702139,074147,388133,744120,202102,49899,316
   > Total Current Liabilities 
51,378
61,591
34,461
56,132
58,528
59,120
64,373
86,287
82,599
62,269
65,973
90,103
101,886
44,399
43,890
36,504
62,579
62,873
40,199
40,277
46,771
45,151
49,194
46,694
46,69449,19445,15146,77140,27740,19962,87362,57936,50443,89044,399101,88690,10365,97362,26982,59986,28764,37359,12058,52856,13234,46161,59151,378
       Short-term Debt 
67,393
65,590
90,494
16,908
21,962
27,945
35,174
35,924
35,235
34,963
33,607
34,432
45,590
0
0
0
0
0
0
0
0
0
0
0
0000000000045,59034,43233,60734,96335,23535,92435,17427,94521,96216,90890,49465,59067,393
       Short Long Term Debt 
67,393
65,590
90,494
16,908
21,962
27,945
35,174
35,924
35,235
34,963
33,607
34,432
45,590
0
0
0
1,661
2,607
1,657
1,657
1,657
1,844
1,728
1,627
1,6271,7281,8441,6571,6571,6572,6071,66100045,59034,43233,60734,96335,23535,92435,17427,94521,96216,90890,49465,59067,393
       Accounts payable 
5,652
16,882
15,002
17,031
9,430
28,968
26,754
31,167
6,642
26,096
29,438
34,266
5,351
42,607
42,158
33,899
10,969
37,195
36,253
36,337
7,599
40,827
45,074
42,744
42,74445,07440,8277,59936,33736,25337,19510,96933,89942,15842,6075,35134,26629,43826,0966,64231,16726,75428,9689,43017,03115,00216,8825,652
       Other Current Liabilities 
18,585
13,284
8,165
21,927
26,122
1,927
2,182
18,933
39,741
947
927
19,307
48,999
148
185
138
21,149
21,447
60
46
1,539
0
0
0
0001,539466021,44721,14913818514848,99919,30792794739,74118,9332,1821,92726,12221,9278,16513,28418,585
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
68,224
62,332
40,236
21,645
143,916
145,653
146,591
128,802
126,960
139,516
138,509
139,076
153,626
145,034
135,375
135,375145,034153,626139,076138,509139,516126,960128,802146,591145,653143,91621,64540,23662,33268,224000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
4,556
6,746
6,453
6,309
5,984
5,680
8,293
8,300
8,218
19,319
18,894
18,419
20,380
19,039
17,550
17,55019,03920,38018,41918,89419,3198,2188,3008,2935,6805,9846,3096,4536,7464,556000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
1
18,298
18,298
173
161
159
333
146
162
152
143
14315216214633315916117318,29818,29810000000000000
       Deferred Long Term Liability 
791
0
0
0
3,588
0
0
0
2,237
0
0
0
4,304
0
0
0
4,443
0
0
0
266
0
0
0
0002660004,4430004,3040002,2370003,588000791
> Total Stockholder Equity
27,467
28,940
6,764
6,212
18,802
31,607
40,665
48,173
61,751
69,067
77,490
90,475
104,679
115,620
127,569
136,253
149,377
158,686
166,516
166,851
170,211
194,021
199,670
200,254
200,254199,670194,021170,211166,851166,516158,686149,377136,253127,569115,620104,67990,47577,49069,06761,75148,17340,66531,60718,8026,2126,76428,94027,467
   Common Stock
4,556
4,789
4,839
5,201
5,790
6,017
6,104
6,172
6,215
6,222
6,257
6,293
6,313
6,350
6,377
6,381
6,388
6,127
6,096
6,258
7,429
7,468
7,469
7,482
7,4827,4697,4687,4296,2586,0966,1276,3886,3816,3776,3506,3136,2936,2576,2226,2156,1726,1046,0175,7905,2014,8394,7894,556
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue167,682
Cost of Revenue-17,826
Gross Profit149,856149,856
 
Operating Income (+$)
Gross Profit149,856
Operating Expense-156,247
Operating Income11,435-6,391
 
Operating Expense (+$)
Research Development59,333
Selling General Administrative81,298
Selling And Marketing Expenses-
Operating Expense156,247140,631
 
Net Interest Income (+$)
Interest Income12,568
Interest Expense-6,091
Net Interest Income7,3436,477
 
Pretax Income (+$)
Operating Income11,435
Net Interest Income7,343
Other Non-Operating Income Expenses-
Income Before Tax (EBT)19,45910,754
EBIT - interestExpense = 17,909
20,570
19,579
Interest Expense6,091
Earnings Before Interest and Taxes (ebit)24,00025,550
Earnings Before Interest and Taxes (ebitda)41,219
 
After tax Income (+$)
Income Before Tax19,459
Tax Provision-5,971
Net Income From Continuing Ops13,48813,488
Net Income13,488
Net Income Applicable To Common Shares15,996
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses2,620
Total Other Income/Expenses Net681-7,343
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
0Q6Q.LSE
18 minutes ago

I found you a Golden Cross on the daily chart of 0Q6Q.LSE.

0Q6Q.LSE Daily Candlestick Chart
0O9Q.LSE
19 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 0O9Q.LSE.

0O9Q.LSE Daily Candlestick Chart
0NPT.LSE
21 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0NPT.LSE.

0NPT.LSE Daily Candlestick Chart
0MGE.LSE
24 minutes ago

I found you a Golden Cross on the daily chart of 0MGE.LSE.

0MGE.LSE Daily Candlestick Chart
0I5O.LSE
27 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0I5O.LSE.

0I5O.LSE Daily Candlestick Chart
APELY.PINK
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of APELY.PINK.

APELY.PINK Daily Candlestick Chart
IVZINNIFTY.NSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IVZINNIFTY.NSE.

IVZINNIFTY.NSE Daily Candlestick Chart
FBT.NYSE ARC
1 hour ago

I found you a Golden Cross on the daily chart of FBT.NYSE ARC.

FBT.NYSE ARC Daily Candlestick Chart
EWW.NYSE ARC
1 hour ago

I found you a Golden Cross on the daily chart of EWW.NYSE ARC.

EWW.NYSE ARC Daily Candlestick Chart
SHRIKRISH.BSE
1 hour ago

I found you a Death Cross on the daily chart of SHRIKRISH.BSE.

SHRIKRISH.BSE Daily Candlestick Chart
BBH.NASDAQ
2 hours ago

I found you a Golden Cross on the daily chart of BBH.NASDAQ.

BBH.NASDAQ Daily Candlestick Chart
KCCA.NYSE ARC
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of KCCA.NYSE ARC.

KCCA.NYSE ARC Daily Candlestick Chart
TUGN.NASDAQ
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of TUGN.NASDAQ.

TUGN.NASDAQ Daily Candlestick Chart
JPST.BATS
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JPST.BATS.

JPST.BATS Daily Candlestick Chart
SMDD.NYSE ARC
2 hours ago

I found you a Death Cross on the daily chart of SMDD.NYSE ARC.

SMDD.NYSE ARC Daily Candlestick Chart
PZA.NYSE ARC
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PZA.NYSE ARC.

PZA.NYSE ARC Daily Candlestick Chart
PTLC.BATS
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PTLC.BATS.

PTLC.BATS Daily Candlestick Chart
TENG.NYSE ARC
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TENG.NYSE ARC.

TENG.NYSE ARC Daily Candlestick Chart
VBB.NASDAQ
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBB.NASDAQ.

VBB.NASDAQ Daily Candlestick Chart
SGTM.PINK
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGTM.PINK.

SGTM.PINK Daily Candlestick Chart
BDRBF.OTCQX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BDRBF.OTCQX.

BDRBF.OTCQX Daily Candlestick Chart
VQS.TO
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of VQS.TO.

VQS.TO Daily Candlestick Chart
CANB.OTCQB
2 hours ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of CANB.OTCQB.

CANB.OTCQB Daily Candlestick Chart
BBB.V
2 hours ago

I found you a MACD Bearish Reversal Divergence on the daily chart of BBB.V.

BBB.V Daily Candlestick Chart
ZAC.V
2 hours ago

I found you a RSI Bearish Reversal Divergence on the daily chart of ZAC.V.

ZAC.V Daily Candlestick Chart